27516476|t|Improved adipose tissue function with initiation of protease inhibitor - only ART
27516476|a|Use of ART containing HIV PIs has previously been associated with toxicity in subcutaneous adipose tissue (SAT), potentially contributing to the development of lipodystrophy and insulin resistance. However, the effect of PIs on SAT function in ART - naive patients independent of other ART classes is unknown. This study aimed to elucidate the effect of initiating PI - only ART on SAT function in ART - naive subjects. In the HIVNAT-019 study, 48 HIV-infected, ART - naive Thai adults commencing PI - only ART comprising lopinavir / ritonavir / saquinavir for 24 weeks underwent assessments of fasting metabolic parameters and body composition. In a molecular substudy, 20 subjects underwent SAT biopsies at weeks 0, 2 and 24 for transcriptional, protein, mitochondrial DNA (mtDNA) and histological analyses. ClinicalTrials.gov registration number: NCT00400738. Over 24 weeks, limb fat increased (+416.4 g, P = 0.023), coinciding with larger adipocytes as indicated by decreased adipocyte density in biopsies (-32.3 cells /mm(2), P = 0.047) and increased mRNA expression of adipogenesis regulator PPARG at week 2 (+58.1%, P = 0.003). Increases in mtDNA over 24 weeks (+600 copies/cell, P = 0.041), decreased NRF1 mRNA expression at week 2 (-33.7%, P < 0.001) and increased COX2 / COX4 protein ratio at week 24 (+288%, P = 0.038) indicated improved mitochondrial function. Despite decreased AKT2 mRNA at week 2 (-28.6%, P = 0.002) and increased PTPN1 mRNA at week 24 (+50.3%, P = 0.016) suggesting insulin resistance, clinical insulin sensitivity [by homeostasis model assessment (HOMA-IR)] was unchanged. Initiation of PI - only ART showed little evidence of SAT toxicity, the changes observed being consistent with a return to health rather than contributing to lipodystrophy. icle
27516476	0	8	Improved	T080	C0332272
27516476	9	23	adipose tissue	T024	C0001527
27516476	24	32	function	T042	C1254358
27516476	38	48	initiation	T169	C1704686
27516476	52	70	protease inhibitor	T121	C0033607
27516476	73	77	only	T081	C0205171
27516476	78	81	ART	T061	C1963724
27516476	89	92	ART	T061	C1963724
27516476	89	92	ART	T061	C1963724
27516476	104	111	HIV PIs	T121	C3536912
27516476	148	156	toxicity	T037	C0600688
27516476	160	187	subcutaneous adipose tissue	T024	C0222331
27516476	189	192	SAT	T024	C0222331
27516476	207	219	contributing	T052	C1880177
27516476	227	238	development	T169	C1527148
27516476	242	255	lipodystrophy	T047	C0023787
27516476	260	278	insulin resistance	T046	C0021655
27516476	293	299	effect	T080	C1280500
27516476	303	306	PIs	T121	C0033607
27516476	303	306	PIs	T121	C0033607
27516476	310	313	SAT	T024	C0222331
27516476	314	322	function	T042	C1254358
27516476	326	329	ART	T061	C1963724
27516476	332	337	naive	T201	C0919936
27516476	338	346	patients	T101	C0030705
27516476	347	358	independent	T078	C0085862
27516476	368	371	ART	T061	C1963724
27516476	426	432	effect	T080	C1280500
27516476	436	446	initiating	T169	C1704686
27516476	447	449	PI	T121	C0033607
27516476	452	456	only	T081	C0205171
27516476	457	460	ART	T061	C1963724
27516476	464	467	SAT	T024	C0222331
27516476	468	476	function	T042	C1254358
27516476	480	483	ART	T061	C1963724
27516476	486	491	naive	T201	C0919936
27516476	492	500	subjects	T101	C0030705
27516476	509	525	HIVNAT-019 study	T062	C0242481
27516476	530	542	HIV-infected	T047	C0019693
27516476	544	547	ART	T061	C1963724
27516476	550	555	naive	T201	C0919936
27516476	556	560	Thai	T098	C0337910
27516476	561	567	adults	T100	C0001675
27516476	568	578	commencing	T052	C3274784
27516476	579	581	PI	T121	C0033607
27516476	584	588	only	T081	C0205171
27516476	589	592	ART	T061	C1963724
27516476	604	613	lopinavir	T109,T121	C0674432
27516476	616	625	ritonavir	T109,T121	C0292818
27516476	628	638	saquinavir	T109,T121	C0286738
27516476	646	651	weeks	T079	C0439230
27516476	662	673	assessments	T058	C1261322
27516476	677	684	fasting	T033	C0015663
27516476	685	694	metabolic	T040	C0025519
27516476	695	705	parameters	T077	C0549193
27516476	710	726	body composition	T032	C0005885
27516476	733	742	molecular	T080	C1521991
27516476	743	751	substudy	T170	C4288169
27516476	756	764	subjects	T101	C0030705
27516476	775	778	SAT	T024	C0222331
27516476	779	787	biopsies	T060	C0005558
27516476	791	796	weeks	T079	C0439230
27516476	813	828	transcriptional	T045	C0040649
27516476	830	837	protein	T063	C1514534
27516476	839	856	mitochondrial DNA	T114,T123	C0012929
27516476	858	863	mtDNA	T114,T123	C0012929
27516476	869	890	histological analyses	T059	C0344441
27516476	892	943	ClinicalTrials.gov registration number: NCT00400738	T062	C0008976
27516476	953	958	weeks	T079	C0439230
27516476	960	978	limb fat increased	T033	C0243095
27516476	1018	1024	larger	T081	C0549177
27516476	1025	1035	adipocytes	T025	C0206131
27516476	1039	1048	indicated	T033	C1444656
27516476	1052	1061	decreased	T081	C0205216
27516476	1062	1071	adipocyte	T025	C0206131
27516476	1072	1079	density	T081	C0162339
27516476	1083	1091	biopsies	T060	C0005558
27516476	1099	1104	cells	T025	C0007634
27516476	1128	1137	increased	T081	C0205217
27516476	1138	1153	mRNA expression	T045	C1515670
27516476	1157	1169	adipogenesis	T044	C0596843
27516476	1170	1179	regulator	T044	C1152862
27516476	1180	1185	PPARG	T028	C1335238
27516476	1189	1193	week	T079	C0439230
27516476	1217	1226	Increases	T169	C0442805
27516476	1230	1235	mtDNA	T114,T123	C0012929
27516476	1244	1249	weeks	T079	C0439230
27516476	1281	1290	decreased	T081	C0205216
27516476	1291	1295	NRF1	T028	C1417846
27516476	1296	1311	mRNA expression	T045	C1515670
27516476	1315	1319	week	T079	C0439230
27516476	1346	1355	increased	T081	C0205217
27516476	1356	1360	COX2	T116,T126	C1565860
27516476	1363	1375	COX4 protein	T116,T123	C0033684
27516476	1376	1381	ratio	T081	C0456603
27516476	1385	1389	week	T079	C0439230
27516476	1412	1421	indicated	T033	C1444656
27516476	1422	1430	improved	T080	C0332272
27516476	1431	1444	mitochondrial	T026	C0026237
27516476	1445	1453	function	T043	C0007613
27516476	1463	1472	decreased	T081	C0205216
27516476	1473	1477	AKT2	T028	C0812230
27516476	1478	1482	mRNA	T114,T123	C0035696
27516476	1486	1490	week	T079	C0439230
27516476	1517	1526	increased	T081	C0205217
27516476	1527	1532	PTPN1	T028	C1335281
27516476	1533	1537	mRNA	T114,T123	C0035696
27516476	1541	1545	week	T079	C0439230
27516476	1580	1598	insulin resistance	T046	C0021655
27516476	1600	1608	clinical	T080	C0205210
27516476	1609	1628	insulin sensitivity	T046	C0920563
27516476	1633	1661	homeostasis model assessment	T058	C1829779
27516476	1663	1670	HOMA-IR	T058	C1829779
27516476	1677	1686	unchanged	T033	C0442739
27516476	1688	1698	Initiation	T169	C1704686
27516476	1702	1704	PI	T121	C0033607
27516476	1707	1711	only	T081	C0205171
27516476	1712	1715	ART	T061	C1963724
27516476	1723	1729	little	T081	C0700321
27516476	1730	1738	evidence	T078	C3887511
27516476	1742	1745	SAT	T024	C0222331
27516476	1746	1754	toxicity	T037	C0600688
27516476	1760	1767	changes	T169	C0392747
27516476	1768	1776	observed	T169	C1441672
27516476	1783	1798	consistent with	T078	C0332290
27516476	1801	1817	return to health	UnknownType	C0548675
27516476	1830	1842	contributing	T052	C1880177
27516476	1846	1859	lipodystrophy	T047	C0023787